{
  "docId": "019de073-9947-75c9-ab6d-01a31b39af7e",
  "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f",
  "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides",
  "authorId": "third-harmonic-bio",
  "authorName": "Third Harmonic Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 3,
  "pageCount": 24,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "appendix_data",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/3",
  "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e",
  "deckJsonHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e.json",
  "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.74,
        "x": 0.224,
        "y": 0.47
      },
      "kind": "list",
      "text": "Use of Proceeds: The Company currently intends to use the net proceeds from this offering, together with its existing cash and cash equivalents, as follows: To advance the continued clinical development of THB001 for the treatment of urticaria... To advance the continued clinical development of THB001 in additional indications... The remainder for potential expansion of the pipeline...",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e792fcb-560b-4ec6-a370-62829fa35f84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.928,
        "x": 0.036,
        "y": 0.72
      },
      "kind": "table",
      "text": "Lock-up: 180 days for the Company, directors, officers, affiliates, and substantially all pre-IPO securityholders Bookrunners: Morgan Stanley, Jefferies, Cowen Co-Manager: LifeSci Capital Expected Pricing: Wednesday September 14, 2022 (Post-Close)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6efc2b3b-9dc5-4e71-9c3b-a26d193f3adf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.32,
        "w": 0.928,
        "x": 0.036,
        "y": 0.15
      },
      "kind": "table",
      "text": "Issuer: Third Harmonic Bio, Inc. Ticker / Exchange: THRD / Nasdaq Shares Offered: 9,000,000 (100% Primary) Filing Range: $16.00 – $18.00 per share Estimated Gross Proceeds: $153,000,000 Over-Allotment Option: 15% (100% Primary)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b00a18d0-dea7-4471-ad7f-bc96c46bfe14",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.038,
        "w": 0.248,
        "x": 0.036,
        "y": 0.065
      },
      "kind": "title",
      "text": "Offering Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fecc9ff-7aa0-4518-aba2-e97c1ebdede3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "9ba38c78-27ed-4466-90cc-553591387c10",
      "evidence": "table/data: Lock-up: 180 days for the Company, directors, officers, affiliates, and substantially all pre-IPO securityholders",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}